Respiratory syncytial virus prevention: past and present strategies

Bibliography

• GROOTHUIS JR, SIMOES EAF, LEVIN MJ et al. AND THE RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN STUDY GROUP: Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. N Engl. J Med. (1993) 329:1524–1530.
   PubMed Web of Science ®Google Scholar
• INSTITUTE OF MEDICINE COMMITTEE ON ISSUES AND PRIORITIES FOR NEW VACCINE DEVELOPMENT: Prospects for immunizing against respiratory syncytial virus. In: New Vaccine Development, Establishing Priorities. National Academy of Sciences Press (1988):397–409.
   Google Scholar
• THE IMPACT-RSV STUDY GROUP: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics (1998) 102(3, Part 0:531–537.
   Google Scholar
• WELLIVER RC: Respiratory syncytial virus immuno-globulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection. Semin. Perinatol. (1998) 22 (1):87–95.
   PubMedGoogle Scholar
• NOBLE V, MURRAY M, WEBB MSC, ALEXANDER J, SWARBRICK AS, MILNER AD: Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch. Dis. Child. (1997) 76:315–319.
   PubMed Web of Science ®Google Scholar
• KAPIKIAN AZ, MITCHELL RH, CHANOCK RM, SHVEDOFF RA, STEWART CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with in inactivated RS virus vaccine. Am. J Epidemiol. (1969) 89 (4):405–421.
   PubMed Web of Science ®Google Scholar
• PIEDRA PA, GRACE S, JEWELL A et al.: Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. (1996) 15(0:23–31.
   Google Scholar
• MEISSNER HC: A novel approach to prevention of RSV infection. Infections In Medicine (Suppl.):20–23.
   Google Scholar
• GROOTHUIS JR, LEVIN MJ, RODRIGUEZ W et al.: Use of intravenous gamma globulin to passively immunize Exp. Opin. Pharmacother. (2000) 1(6) high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group. Antimicrob. Agents Chemother. (1991) 35 (7) :1469–1473.
   Google Scholar
• MEISSNER HC, FULTON DR, GROOTHUIS JR et al.: Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimi-crob. Agents Chemother. (1993) 37:1655–1658.
   PubMed Web of Science ®Google Scholar
• GROOTHUIS JR, SIMOES EAF, HEMMING VG AND THE RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN GROUP: Respiratory syncytial (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics (1995) 95:463–467.
   PubMed Web of Science ®Google Scholar
• THE PREVENT STUDY GROUP: Reduction of respiratorysyncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics (1997) 99:93–99.
   PubMed Web of Science ®Google Scholar
• SIMOES EAF, SONDHEIMER HM, TOP FH et al. AND THECARDIAC STUDY GROUP: Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr. (1998) 133:492–499.
   PubMedGoogle Scholar
• SIMOES EAF, GROOTHUIS JR, TRISTRAM DA et al: Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children. Pediatr. (1996) 192:214–219.
   Google Scholar
• JOHNSON S, OLIVER C, PRINCE GA et al: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect. Dis. (1997) 176:1215–1224.
   PubMed Web of Science ®Google Scholar
• WALSH EE, SCHLESINGER JJ, BRANDRISS MW: Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Iminun. (1984) 43 (2):756–758.
   PubMedGoogle Scholar
• BEELER JA, COELINGH K: Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virof (1989) 63 (7): 2941–2950.
   PubMed Web of Science ®Google Scholar
• SAEZ-LLORENS X, CASTANO E, NULL D et al. AND THE MEDI-493 STUDY GROUP: Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. (1998) 17(9):787–791.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAN KN, WEISMAN LE, RHODES T et al: Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. (1998) 17(2):110–115.
   PubMed Web of Science ®Google Scholar
• MALLEY R, DEVINCENZO J, RAMILO 0 etal.: Reduction ofrespiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. (1998) 178 (6):1555–1561.
   Google Scholar
• AMERICAN ACADEMY OF PEDIATRICS COMMITTEE ONINFECTIOUS DISEASE AND COMMITTEE ON FETUS AND NEWBORN: Prevention of respiratory syncytial virus infections: indications for the use of Palivizumab and update on the use of RSV-IGIV. Pediatrics (1998) 102 (5):1211–1216.
   PubMedGoogle Scholar
• JOFFE S, ESCOBAR GJ, BLACK SB, ARMSTRONG MA, LIEUTA: Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics (1999) 104(4, Part 1):894–899.
   Google Scholar
• STEVENS TP, SINKIN RA, HALL CB, MANISCALCO WM, MCCONNOCHIE KM: Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch. Pediatr. Adolesc. Med. (2000) 154 (1):55–61.
   PubMedGoogle Scholar
• THOMAS M, BEDFORD-RUSSELL A, SHARLAND M: Hospitalisation for RSV infection in ex -preterm infants -implications for use of RSVimmune globulin. Arch. Dis. Child. (2000). (In Press).
   Google Scholar
• JOFFE S, RAY GT, ESCOBAR GJ, BLACK SB, LIEU TA:Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics (1999) 104 (3):419–427.
   PubMedGoogle Scholar